课题基金 / 基金详情

Role of JNK and p38 MAPK signalling in diabetic nephropathy

Role of JNK and p38 MAPK signalling in diabetic nephropathy
JNK 和 p38 MAPK 信号在糖尿病肾病中的作用
批准号:
nhmrc : 338517
负责人:
A/Pr David Nikolic-Paterson
金额:
$30.31万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2005
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2005-01-01 至 2007-12-31

项目摘要

项目成果

A/Pr David Nikolic-Paterson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Renal failure is a major health problem in our community. Patients who progress to end-stage renal failure are dependent upon lifelong dialysis or transplantation (an expensive and complex treatment). The past decade has seen a dramatic increase in the number of patients developing end-stage renal failure, mainly due to increasing rates of diabetic kidney disease. Indeed, the recent AusDiab nationwide survey that identified diabetes or glucose intolerance (a precursor to diabetes) is now present in up to 25% of the adult Australian population. Around 50% of diabetics develop kidney disease and, despite recent advances in better control of blood glucose and blood pressure, kidney disease in most diabetic patients will inexorably progress to end-stage renal failure. Therefore, there is an urgent need to improve treatment strategies in diabetic patients to avoid kidney failure. We have identified a group of proteins (enzymes called JNK and p38) within cells that play a causal role in the development of non-diabetic forms of kidney disease. Most recently, we have shown that an increase in the activity of these proteins (JNK and p38) is associated with the development of human and experimental diabetic kidney disease. Therefore, this project will block the action of JNK and p38 using two complementary approaches (pharmaceutical drugs and genetically modified mice) to determine whether targeting these proteins can suppress the development of diabetic kidney disease. In addition, there is evidence to suggest that blockade of these proteins may have a beneficial impact upon insulin resistance and elevated blood glucose in type 2 diabetes. If these postulates are proven, this will provide a well-defined therapeutic target for the treatment of diabetic kidney disease, and perhaps diabetes itself. Furthermore, since inhibitors of these proteins are already in clinical trials for other indications, targeting this mechanism in diabetic kidney disease is a realistic goal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TGF-beta/Smad signalling in macrophage-mediated renal fibrosis.
  • 批准号:
    nhmrc : 1122073
  • 项目类别:
    Project Grants
  • 资助金额:
    $46.66万
  • 财政年份:
    2017
  • 负责人:
    A/Pr David Nikolic-Paterson
  • 依托单位:
Defining the central role of podocyte depletion in the development, progression and management of glomerular disease
  • 批准号:
    nhmrc : GNT1121793
  • 项目类别:
    Project Grants
  • 资助金额:
    $69.09万
  • 财政年份:
    2017
  • 负责人:
    A/Pr David Nikolic-Paterson
  • 依托单位:
Defining the central role of podocyte depletion in the development, progression and management of glomerular disease
  • 批准号:
    nhmrc : 1121793
  • 项目类别:
    Project Grants
  • 资助金额:
    $47.17万
  • 财政年份:
    2017
  • 负责人:
    A/Pr David Nikolic-Paterson
  • 依托单位:
TGF-beta/Smad signalling in macrophage-mediated renal fibrosis.
  • 批准号:
    nhmrc : GNT1122073
  • 项目类别:
    Project Grants
  • 资助金额:
    $68.37万
  • 财政年份:
    2017
  • 负责人:
    A/Pr David Nikolic-Paterson
  • 依托单位:
国内基金
海外基金
丁酸通过抑制p38/ERK/JNK信号通路重建Treg/Th17平衡缓解艰难梭菌结肠炎的机制研究
DUSP10通过抑制JNK/P38延缓肾脏缺血再灌注纤维化的关键机制研究
  • 批准号:
    2026JJ50647
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    郭勇
  • 依托单位:
CDH5介导p38/JNK通路调控糖尿病视网膜病变的分子机制及干预探索
  • 批准号:
    2026JJ80392
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    王桂芳
  • 依托单位:
ZBED3激活ASK1-JNK/p38信号通路促进NASH进展的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    罗小河
  • 依托单位: